1-十六烷基-2-氮杂酰基-sn-甘油-3-磷酸胆碱 | 354583-69-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: 1-十六烷基-2-氮杂酰基-sn-甘油-3-磷酸胆碱
• 英文名称: Azelaoyl PAF
• 英文别名: [(2R)-2-(8-carboxyoctanoyloxy)-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 354583-69-0
• 化学式: C33H66NO9P
• 分子量: 651.9
• InChiKey: ZDFOCDTXDPKJKA-WJOKGBTCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  44
• 可旋转键数：
  34
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  131
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-羟甲基糠醛 、 1-十六烷基-2-氮杂酰基-sn-甘油-3-磷酸胆碱 在 sodium hydride 、 4-二甲氨基吡啶 、 N-羟基丁二酰亚胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 生成
  参考文献：
  名称：

  ACTIVATED NANOTHERAPY FOR SICKLE CELL DISEASE

  摘要：

  We disclose here the nano-enabled delivery of highly potent 5 -hydroxymethyl furfural (5-HMF) to sickled blood cells in patients. 5-HMF, a superior antisickling agent, has been formulated to address the limitations of existing treatment modalities arising from disfavorable pharmacokinetics of the drug compound. Specifically, two complementary 5-HMF prodrugs are integrated as a "protected" biocompatible composite nanoparticle designed to readily fuse with RBCs and be amenable to transdermal delivery (5-HMF-grafted-phospholipid layered over a sucrose-derived graphitic carbon dot core). These RBC-targeted, protected, biocompatible, self-assembled 5-HMF prodrug nanoparticles for sickle cell disease are the first in class technology for offering a treatment for sickle cell disease which has improved potency, targeted payload delivery, and extended release with the red blood cells with enhanced pharmacodynamic effect in a treated patient.

  公开号：

  WO2024112943A1

文献信息

• PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF
  申请人：Lanza Gregory M.

  公开号：US20130122100A1

  公开（公告）日：2013-05-16

  Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents.

  本发明涉及一种纳米颗粒，包括一种前药和连接到磷脂的前药，其中连接部位促进了颗粒和细胞膜的融合，从而使前药从纳米颗粒释放到目标细胞或细胞膜内的位点。还公开了制备和使用纳米颗粒及其组分的方法。
• ACTIVATED NANOTHERAPY FOR SICKLE CELL DISEASE
  申请人：[en]UNIVERSITY OF MARYLAND, BALTIMORE

  公开号：WO2024112943A1

  公开（公告）日：2024-05-30

  We disclose here the nano-enabled delivery of highly potent 5 -hydroxymethyl furfural (5-HMF) to sickled blood cells in patients. 5-HMF, a superior antisickling agent, has been formulated to address the limitations of existing treatment modalities arising from disfavorable pharmacokinetics of the drug compound. Specifically, two complementary 5-HMF prodrugs are integrated as a "protected" biocompatible composite nanoparticle designed to readily fuse with RBCs and be amenable to transdermal delivery (5-HMF-grafted-phospholipid layered over a sucrose-derived graphitic carbon dot core). These RBC-targeted, protected, biocompatible, self-assembled 5-HMF prodrug nanoparticles for sickle cell disease are the first in class technology for offering a treatment for sickle cell disease which has improved potency, targeted payload delivery, and extended release with the red blood cells with enhanced pharmacodynamic effect in a treated patient.